Therapeutic Development of Immune Checkpoint Inhibitors

被引：26

作者：

Wang, Jilin ^{[1
]}

Yang, Teddy ^{[2
]}

Xu, Jie ^{[3
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Inst Digest Dis, Renji Hosp, Sch Med, Shanghai 200001, Peoples R China

[2] Shanghai ChemPartner Co Ltd, Biol Discovery, 965 Halei Rd Bldg 10,Zhangjiang Hitech Pk, Shanghai, Peoples R China

[3] Fudan Univ, Zhongshan Xuhui Hosp, Inst Biomed Sci, Shanghai 200032, Peoples R China

来源：

REGULATION OF CANCER IMMUNE CHECKPOINTS: MOLECULAR AND CELLULAR MECHANISMS AND THERAPY | 2020年 / 1248卷

关键词：

Immune checkpoint blocker; CTLA-4; PD-1; PD-L1; CELL LUNG-CANCER; CD8(+) T-CELLS; RESISTANT PROSTATE-CANCER; OPEN-LABEL PHASE-3; DOUBLE-BLIND; SINGLE-ARM; HEPATOCELLULAR-CARCINOMA; ADVANCED MELANOMA; ANTI-CTLA-4; ANTIBODY; ANTITUMOR-ACTIVITY;

D O I：

10.1007/978-981-15-3266-5_23

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint blockade (ICB) has been proven to be an effective strategy for enhancing the effector activity of anti-tumor T cells, and checkpoint blockers targeting CTLA-4, PD-1, and PD-L1 have displayed strong and durable clinical responses in certain cancer patients. The new hope brought by ICB therapy has led to the boost in therapeutic development of ICBs in recent years. Nonetheless, the therapeutic efficacy of ICBs varies substantially among cancer types and patients, and only a proportion of cancer patients could benefit from ICBs. The emerging targets and molecules for enhancing anticancer immunity may bring additional therapeutic opportunities for cancer patients. The current challenges in the ICB therapy have been discussed, aimed to provide further strategies for maximizing the efficacy of ICB therapy.

引用

页码：619 / 649

页数：31

共 195 条

[1] Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma [J].

Alexander, Marliese ;

Mellor, James D. ;

McArthur, Grant ;

Kee, Damien .

MEDICAL JOURNAL OF AUSTRALIA, 2014, 201 (01) :49-53

[2] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[3] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[4] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[5] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].

Antonia, Scott ;

Goldberg, Sarah B. ;

Balmanoukian, Ani ;

Chaft, Jamie E. ;

Sanborn, Rachel E. ;

Gupta, Ashok ;

Narwal, Rajesh ;

Steele, Keith ;

Gu, Yu ;

Karakunnel, Joyson J. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2016, 17 (03) :299-308

[6] Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade [J].

Ariyan, Charlotte E. ;

Brady, Mary Sue ;

Siegelbaum, Robert H. ;

Hu, Jian ;

Bello, Danielle M. ;

Rand, Jamie ;

Fisher, Charles ;

Lefkowitz, Robert A. ;

Panageas, Kathleen S. ;

Pulitzer, Melissa ;

Vignali, Marissa ;

Emerson, Ryan ;

Tipton, Christopher ;

Robins, Harlan ;

Merghoub, Taha ;

Yuan, Jianda ;

Jungbluth, Achim ;

Blando, Jorge ;

Sharma, Padmanee ;

Rudensky, Alexander Y. ;

Wolchok, Jedd D. ;

Allison, James P. .

CANCER IMMUNOLOGY RESEARCH, 2018, 6 (02) :189-200

[7] A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors [J].

Arnaud-Coffin, Patrick ;

Maillet, Denis ;

Gan, Hui K. ;

Stelmes, Jean-Jacques ;

You, Benoit ;

Dalle, Stephane ;

Peron, Julien .

INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (03) :639-648

[8] Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future? [J].

Ascierto, Paolo A. ;

McArthur, Grant A. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15

[9] Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer [J].

Bang, Yung-Jue ;

Cho, Jae Yong ;

Kim, Yeul Hong ;

Kim, Jin Won ;

Di Bartolomeo, Maria ;

Ajani, Jaffer A. ;

Yamaguchi, Kensei ;

Balogh, Agnes ;

Sanchez, Teresa ;

Moehler, Markus .

CLINICAL CANCER RESEARCH, 2017, 23 (19) :5671-5678

[10] FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma [J].

Barone, Amy ;

Hazarika, Maitreyee ;

Theoret, Marc R. ;

Mishra-Kalyani, Pallavi ;

Chen, Huanyu ;

He, Kun ;

Sridhara, Rajeshwari ;

Subramaniam, Sriram ;

Pfuma, Elimika ;

Wang, Yaning ;

Li, Hongshan ;

Zhao, Hong ;

Zirkelbach, Jeanne Fourie ;

Keegan, Patricia ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2017, 23 (19) :5661-5665

← 1 2 3 4 5 6 7 8 9 10 →